Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeFoLMe study of metformin added to FOLFOX + bevacizumab in metastatic colorectal cancer
ChiCTR-IPR-17013973Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin in colorectal cancer (CRC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-IPR-17013973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013973.